Investigation of the Effect of Upper Gastrointestinal Disease on the Pharmacokinetics of Oral Semaglutide in Subjects With Type 2 Diabetes.
NCT02877355
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
55
Enrollment
INDUSTRY
Sponsor class
Conditions
Diabetes
Diabetes Mellitus, Type 2
Interventions
DRUG:
semaglutide
Sponsor
Novo Nordisk A/S